Astellas Finally Wins FDA Approval For Prograf Successor
This article was originally published in The Pink Sheet Daily
Female mortality rate among liver transplant patients had been a major obstacle to approval for extended-release tacrolimus, which was first filed in 2005. But the once-daily drug is now approved for kidney transplant patients.
You may also be interested in...
Veloxis sues FDA after agency declines to approve to its extended-release immunosuppressant, Envarsus XR, until exclusivity for Astellas’ Astagraf XL expires in 2016.
On heels of second “approvable” letter for kidney transplant rejection, FDA issues another approvable for liver indication.
Extended FDA review period up soon for long-lasting Prograf in liver transplant patients.